23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › LEXICON PHARMACEUTICALS INC. › 2023-2024

LEXICON PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and LEXICON PHARMACEUTICALS INC.’s Form 8-K, filed May 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 110Asset managers, any item
  • 809Fund votes
  • May 10, 2024Meeting date

Results at a glance

Meeting of May 10, 2024: 6 items on LEXICON PHARMACEUTICALS INC.’s Form 8-K, filed May 10, 2024: 6 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LEXICON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by LEXICON PHARMACEUTICALS INC.

These tallies are LEXICON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LEXICON PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 10, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Philippe J. Amouyal 241,812,501---- 18,607,73229,015,729 93%Passed (calculated)—
Elect Director: Lonnel Coats 247,448,636---- 12,971,59729,015,729 95%Passed (calculated)—
Elect Director: Diane E. Sullivan 259,435,040---- 985,19329,015,729 99.6%Passed (calculated)—
2. Ratification and approval of the Company's Sixth Amended and Restated Certificate of Incorporation 160,676,3911,433,806211,035 ---- 99.1%Passed (calculated)—
3. Advisory vote to approve the compensation paid to the Company’s named executive officers 253,593,3226,203,593623,318 --29,015,729 98%Passed (calculated)—
4. Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2024 286,136,7662,884,465414,731 ---- 99.0%Passed (calculated)—

Source: LEXICON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 10, 2024 — read the filing on EDGAR.

How asset managers voted at the LEXICON PHARMACEUTICALS INC. 2023-2024 meeting

110 asset managers disclosed a vote on at least one LEXICON PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Diane E. Sullivan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 259,435,040WITHHELD: 985,193
Details: description as filed, official tally, votes by 37 asset managers

Description as filed by funds: Election of Directors: Diane E. Sullivan

LEXICON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Diane E. Sullivan”): 259,435,040 for, 985,193 withheld, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 12,324,218 for, 8,867 withheld.

FOR
FOR: 12,324,218WITHHOLD: 8,867
Largest asset managers voting on “Election of Directors: Diane E. Sullivan” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,496,0300 00For
BlackRock2,813,8040 00For
Vanguard2,190,2620 00For
Columbia Threadneedle1,204,2030 00For
Charles Schwab616,2970 00For
TIAA592,5150 00For
JPMorgan478,6510 00For
Equitable240,3120 00For
QUANTITATIVE MASTER SERIES LLC159,5050 00For
Lincoln Financial76,5160 00For
ETFis Series Trust I60,8010 00For
Northern Trust51,9960 00For
Dimensional47,3810 00For
Invesco38,5910 00For
ProShares33,5380 00For
Pacific Life32,2460 00For
Altium Capital Management LP27,6500 00For
Bridge Builder Trust26,6360 00For
Brighthouse26,4690 00For
SEI17,1050 00For
Prudential/PGIM15,6090 00For
AIG/SunAmerica14,9450 00For
DWS14,4030 00For
Principal10,5340 00For
Voya9,0630 00For

Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).

Elect Director: Lonnel Coats

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 247,448,636WITHHELD: 12,971,597
Details: description as filed, official tally, votes by 37 asset managers

Description as filed by funds: Election of Directors: Lonnel Coats

LEXICON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lonnel Coats”): 247,448,636 for, 12,971,597 withheld, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 11,489,113 for, 843,672 withheld, 300 abstained.

FOR
FOR: 11,489,113ABSTAIN: 300WITHHOLD: 843,672
Largest asset managers voting on “Election of Directors: Lonnel Coats” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,496,0300 00For
BlackRock2,813,8040 00For
Vanguard2,190,2620 00For
Columbia Threadneedle1,204,2030 00For
Charles Schwab616,2970 00For
TIAA00 0592,515Withhold
JPMorgan478,6510 00For
Equitable240,3120 00For
QUANTITATIVE MASTER SERIES LLC159,5050 00For
Lincoln Financial76,5160 00For
ETFis Series Trust I00 060,801Withhold
Northern Trust51,9960 00For
Dimensional00 047,381Withhold
Invesco00 038,591Withhold
ProShares00 033,538Withhold
Pacific Life32,2460 00For
Altium Capital Management LP27,6500 00For
Bridge Builder Trust26,6360 00For
Brighthouse9,5820 016,887Mixed
SEI17,1050 00For
Prudential/PGIM15,6090 00For
AIG/SunAmerica00 014,945Withhold
DWS00 014,403Withhold
Principal00 010,534Withhold
Voya9,0630 00For

Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).

Elect Director: Philippe J. Amouyal

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 241,812,501WITHHELD: 18,607,732
Details: description as filed, official tally, votes by 37 asset managers

Description as filed by funds: Election of Directors: Philippe J. Amouyal

LEXICON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Philippe J. Amouyal”): 241,812,501 for, 18,607,732 withheld, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 8,154,872 for, 4,151,277 withheld, 26,936 abstained.

FORWITHHOLD
FOR: 8,154,872ABSTAIN: 26,936WITHHOLD: 4,151,277
Largest asset managers voting on “Election of Directors: Philippe J. Amouyal” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,496,0300 00For
BlackRock00 02,813,804Withhold
Vanguard2,190,2620 00For
Columbia Threadneedle1,204,2030 00For
Charles Schwab616,2970 00For
TIAA00 0592,515Withhold
JPMorgan478,6510 00For
Equitable00 0240,312Withhold
QUANTITATIVE MASTER SERIES LLC00 0159,505Withhold
Lincoln Financial00 076,516Withhold
ETFis Series Trust I00 060,801Withhold
Northern Trust51,9960 00For
Dimensional00 047,381Withhold
Invesco38,5910 00For
ProShares00 033,538Withhold
Pacific Life00 032,246Withhold
Altium Capital Management LP27,6500 00For
Bridge Builder Trust00 26,6360Abstain
Brighthouse9,5820 016,887Mixed
SEI17,1050 00For
Prudential/PGIM15,6090 00For
AIG/SunAmerica00 014,945Withhold
DWS00 014,403Withhold
Principal00 010,534Withhold
Voya00 09,063Withhold

Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).

Ratification and approval of the Company's Sixth Amended and Restated Certificate of Incorporation

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 160,676,391AGAINST: 1,433,806
Details: official tally, votes by 37 asset managers

LEXICON PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification and approval of the the Company's Sixth Amended and Restated Certificate of Incorporation”): 160,676,391 for, 1,433,806 against, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 12,333,085 for.

FOR
FOR: 12,333,085
Largest asset managers voting on “Ratification and approval of the Company's Sixth Amended and Restated Certificate of Incorporation” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,496,0300 00For
BlackRock2,813,8040 00For
Vanguard2,190,2620 00For
Columbia Threadneedle1,204,2030 00For
Charles Schwab616,2970 00For
TIAA592,5150 00For
JPMorgan478,6510 00For
Equitable240,3120 00For
QUANTITATIVE MASTER SERIES LLC159,5050 00For
Lincoln Financial76,5160 00For
ETFis Series Trust I60,8010 00For
Northern Trust51,9960 00For
Dimensional47,3810 00For
Invesco38,5910 00For
ProShares33,5380 00For
Pacific Life32,2460 00For
Altium Capital Management LP27,6500 00For
Bridge Builder Trust26,6360 00For
Brighthouse26,4690 00For
SEI17,1050 00For
Prudential/PGIM15,6090 00For
AIG/SunAmerica14,9450 00For
DWS14,4030 00For
Principal10,5340 00For
Voya9,0630 00For

Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).

Advisory vote to approve the compensation paid to the Company’s named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 253,593,322AGAINST: 6,203,593
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Advisory vote to approve the compensation paid to the Company's named executive officers

LEXICON PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory vote to approve the compensation paid to the Company’s named executive officers”): 253,593,322 for, 6,203,593 against, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 36 asset managers voting on “Advisory vote to approve the compensation paid to the Company's named executive officers” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,496,0300 00For
BlackRock2,813,8040 00For
Vanguard2,190,2620 00For
Columbia Threadneedle01,204,203 00Against
Charles Schwab616,2970 00For
TIAA592,5150 00For
JPMorgan478,6510 00For
Equitable20,371219,941 00Mixed
QUANTITATIVE MASTER SERIES LLC159,5050 00For
Lincoln Financial76,5160 00For
ETFis Series Trust I60,8010 00For
Northern Trust51,9960 00For
Dimensional047,381 00Against
Invesco38,5910 00For
ProShares33,5380 00For
Pacific Life32,2460 00For
Bridge Builder Trust26,6360 00For
Brighthouse26,4690 00For
SEI017,105 00Against
Prudential/PGIM15,6090 00For
AIG/SunAmerica14,9450 00For
DWS14,4030 00For
Principal10,5340 00For
Voya9,0630 00For
Texas Capital Funds Trust8,8950 00For

Fund voting reports, all 36 managers: 10,807,937 for, 1,497,498 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 90 asset managers voting on “Advisory vote to approve the compensation paid to the Company's named executive officers” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Point729,216,6000 00For
Fidelity8,502,3270 00For
BlackRock2,227,0237,099 00For
ORBIMED ADVISORS LLC1,771,8100 00For
State Street1,397,255349 00For
PNC BANK, NATIONAL ASSOCIATION0804,111 00Against
JPMorgan752,9160 00For
Charles Schwab616,2970 00For
Nuveen594,3820 00For
Wellington0568,106 00Against
PINNACLE ASSOCIATES LTD531,6900 00For
Northern Trust464,3970 00For
AllianceBernstein0219,941 00Against
MELLON INVESTMENTS Corp197,8390 00For
AMERIPRISE FINANCIAL INC0175,849 00Against
Vanguard105,1710 00For
STIFEL NICOLAUS & CO INC \MO\101,3320 00For
BBR PARTNERS, LLC100,0000 00For
Cerity Partners LLC095,512 00Against
GREAT POINT PARTNERS LLC92,1650 00For
Natixis086,788 00Against
GEODE CAPITAL MANAGEMENT, LLC72,2850 00For
Goldman Sachs62,1850 00For
Invesco62,1780 00For
Two Sigma60,4420 00For

Institutional-manager reports, all 90 managers: 27,229,678 for, 2,142,639 against, 3,300 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 286,136,766AGAINST: 2,884,465
Details: description as filed, official tally, votes by 37 asset managers

Description as filed by funds: Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent auditors for the fiscal year ending December 31, 2024

LEXICON PHARMACEUTICALS INC.’s own tally for this item (“4. Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2024”): 286,136,766 for, 2,884,465 against, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 12,333,085 for.

FOR
FOR: 12,333,085
Largest asset managers voting on “Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent auditors for th” at LEXICON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,496,0300 00For
BlackRock2,813,8040 00For
Vanguard2,190,2620 00For
Columbia Threadneedle1,204,2030 00For
Charles Schwab616,2970 00For
TIAA592,5150 00For
JPMorgan478,6510 00For
Equitable240,3120 00For
QUANTITATIVE MASTER SERIES LLC159,5050 00For
Lincoln Financial76,5160 00For
ETFis Series Trust I60,8010 00For
Northern Trust51,9960 00For
Dimensional47,3810 00For
Invesco38,5910 00For
ProShares33,5380 00For
Pacific Life32,2460 00For
Altium Capital Management LP27,6500 00For
Bridge Builder Trust26,6360 00For
Brighthouse26,4690 00For
SEI17,1050 00For
Prudential/PGIM15,6090 00For
AIG/SunAmerica14,9450 00For
DWS14,4030 00For
Principal10,5340 00For
Voya9,0630 00For

Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).

Largest LEXICON PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 246,236,753 shares outstanding at the time of that meeting.

Fund voting reports: top LEXICON PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve the compensation paid to the Company's named executive officers”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 1.42%
2BlackRock 1.14%
3Vanguard 0.89%
4Columbia Threadneedle 0.49%
5Charles Schwab 0.25%
6TIAA 0.24%
7JPMorgan 0.19%
8Equitable 0.10%
9QUANTITATIVE MASTER SERIES LLC 0.06%
10Lincoln Financial 0.03%
Institutional-manager reports: top LEXICON PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve the compensation paid to the Company's named executive officers”, 2023-2024
#Asset manager % of shares outstanding
1Point72 3.74%
2Fidelity 3.45%
3BlackRock 0.91%
4ORBIMED ADVISORS LLC 0.72%
5State Street 0.57%
6PNC BANK, NATIONAL ASSOCIATION 0.33%
7JPMorgan 0.31%
8Charles Schwab 0.25%
9Nuveen 0.24%
10Wellington 0.23%

Reported LEXICON PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

LEXICON PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Invus, L.P., Invus Public Equities, L.P., Invus US Partners, LLC and Artal International S180,550,588 —Proxy statement (DEF 14A), proxy filed March 26, 2024
FMR (Fidelity)38,679,748 —Form 13F, quarter ended March 31, 2024
FMR LLC36,935,512 —Proxy statement (DEF 14A), proxy filed March 26, 2024
Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Tra24,435,632 —Proxy statement (DEF 14A), proxy filed March 26, 2024
Vanguard Group9,521,874 —Form 13F, quarter ended March 31, 2024
Raymond Debbane6,792,051 —Proxy statement (DEF 14A), proxy filed March 26, 2024
BlackRock3,394,972 —Form 13F, quarter ended March 31, 2024
Geode Capital2,389,137 —Form 13F, quarter ended March 31, 2024
State Street1,987,510 —Form 13F, quarter ended March 31, 2024
Lonnel Coats1,098,068 —Proxy statement (DEF 14A), proxy filed March 26, 2024

Percentages above are of 246,236,753 shares outstanding, as reported by LEXICON PHARMACEUTICALS INC. on its Form 10-Q dated April 29, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At LEXICON PHARMACEUTICALS INC.'s shareholder meeting held May 10, 2024, in the 2023-2024 proxy season, 110 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 809 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve the compensation paid to the Company's named executive officers — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LEXICON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 10, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LEXICON PHARMACEUTICALS INC.’s 10-Q dated April 29, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

LEXICON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “LEXICON PHARMACEUTICALS (LXRX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/lexicon-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.